GRAIL Inc. (GRAL)
$140.35+2.17%Close
BUYRECOVERY · day 47
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.0B
- Beta
- 3.25
- P/E (TTM)
- -14.39
- Short % float
- 20.38%
- Days to cover
- 4.1
- SI change
- -6.5%
- 1W
- +2.24%
- 1M
- +85.82%
- vs SPY 1W
- +2.37%
- vs SPY 1M
- +83.31%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$56.7BBULLQ 30$395.65-0.53%
- GHSELLGuardant Health, Inc.$21.8BBEARQ 23$162.09-0.43%
- BLLNSELLBillionToOne, Inc.$4.3BCRISISQ -9$94.44+1.47%
- WGSSELLGeneDx Holdings Corp.$1.9BCRISISQ -3$64.96+1.79%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$15.85+0.32%
- CSTLSELLCastle Biosciences, Inc.$1.0BRECOVERYQ 11$32.88+0.37%
- FLGTSELLFulgent Genetics, Inc.$598MRECOVERYQ 13$21.06-1.91%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on GRAL?
- LOPJLB’s latest quantitative signal on GRAIL Inc. (GRAL) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is GRAL in?
- GRAIL Inc. (GRAL) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does GRAIL Inc. (GRAL) do?
- GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides de…